Oncology and Cancer Immunology Research Oncology and Cancer Immunology Research Find out more about our research and development in oncology and cancer immunology.
Acquisition expands research in cancer immunology Acquisition expands research in cancer immunology Boehringer Ingelheim acquires Abexxa to develop novel cancer therapies by leveraging Abexxa’s unique technology and breakthrough antibody-based drugs.
SIRPα Cancer Immunology Research SIRPα Cancer Immunology Research Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Four Pillars Cancer Immunology Four Pillars Cancer Immunology Boehringer Ingelheim is focusing cancer immunology research on T cell engagers, cancer vaccines, oncolytic viruses and immune & stromal modulation
“My ultimate goal is to cure cancer” “My ultimate goal is to cure cancer” Norbert Kraut, our Global Head of Cancer Research, shares how we are advancing science to bring new treatment options for people living with cancer.
Accelerating new cancer medicines in partnership with CBmed Accelerating new cancer medicines in partnership with CBmed Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
New exchange platform with Harbin Research Institute New exchange platform with Harbin Research Institute Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
Why cancer care is personal for us Why cancer care is personal for us At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies License deal with A*STAR to develop cancer antibodies
The power of patient advocacy in cancer care The power of patient advocacy in cancer care Larry, a retired US Navy veteran, and Jeff, UICC President, have more in common than a cancer diagnosis: they share a passion for patient empowerment.
Taking Cancer on Through Flavour Taking Cancer on Through Flavour Recipes developed specifically for people living with cancer. Contributions from a chef, a dietitian, and a cancer survivor.
Europe needs a vibrant research eco-system Europe needs a vibrant research eco-system At this week's EFPIA Days in Brussels, stakeholders will discuss how to re-establish a research-friendly eco-system in Europe.
Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio Second cancer immunotherapy partnership with 3T Bio
Larry’s Story: Advocating for people with lung cancer Larry’s Story: Advocating for people with lung cancer In 2013, Larry was diagnosed with non-small cell lung cancer. Learn how his diagnosis led him on a journey of patient advocacy for others with cancer.
Targeting MDM2-p53 in cancer: The story of brigimadlin Targeting MDM2-p53 in cancer: The story of brigimadlin Learn about the discovery of Brigimadlin, our MDM2-p53 antagonist, that is being developed for the treatment of dedifferentiated liposarcoma, a rare cancer
Experiences of living with cancer Experiences of living with cancer We know from speaking with people living with cancer and their loved ones, that it’s often the small moments that can be the most significant.
2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award sponsorship 2020 European PRRS Research Award: Boehringer Ingelheim calls for submissions
T-cell engagers: Reawakening T-cells to fight cancer T-cell engagers: Reawakening T-cells to fight cancer Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
expanded-collaboration-MD-Anderson expanded-collaboration-MD-Anderson The continued collaboration aims to accelerate the development of KRAS and TRAILR2 compounds in lung cancer
Taking Cancer On: The Podcast Taking Cancer On: The Podcast From early stage discovery to clinical trials and approval, we’re Taking Cancer On.
Veterinary oncology - cancer treatment Veterinary oncology - cancer treatment Our R&D team's efforts toward finding new cancer treatments for pets
Bringing focus to biliary tract and pancreatic cancers Bringing focus to biliary tract and pancreatic cancers The Brightline-2 clinical trial is studying our investigational MDM2-p53 antagonist for people with advanced biliary tract and pancreatic cancers.
Protein Degraders in Cancer Protein Degraders in Cancer Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach